Rosiglitazone Quantification In Rat Plasma Using High Performance Liquid Chromatography With Mass Spectrometric Detection And Its Application To Pre-Clinical Pharmacokinetic Studies

References

1. 1.↵
   1. Young P. W.,
   2. Buckle D. R.,
   3. Cantello B. C.

   Identification of high-affinity binding sites for the insulin sensitizer-rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J. Pharmacol. Exp. Ther. 1998, 284 (2), 751–759.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Patel J.,
   2. Miller E.,
   3. Patwardhan R.

   Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients, Diabetes. 1998, 47 (Suppl. 1), A17.

   OpenUrl
3. 3.↵
   1. Lehmann J. M.,
   2. Moore L. B.,
   3. Smith-Oliver T. A.

   An anti-diabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem. 1995, 270 (22), 12953–12956.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Willson T. M.,
   2. Cobb J. E.,
   3. Cowan D. J.,
   4. Wiethe R. W.,
   5. Correa I. D.,
   6. Prakash S. R.,
   7. Beck K. D.,
   8. Moore L. B.,
   9. Kliewer S. A.,
   10. Lehmann J. M.

   The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 1996, 39 (3), 665–668.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Gaal L. V.,
   2. Scheen A. J.

   Are all the glitazones same? Diabetes Metab. Res. Rev. 2002, 18 (Supp 2), S4.

   OpenUrl
6. 6.↵
   1. Miller A. K.,
   2. Inglis A. L.,
   3. Thompson K.,
   4. Davie C. C.,
   5. Schenker S.,
   6. Blum R.,
   7. Jorkasky D.,
   8. Freed M. I.

   Effect of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG). Clin. Pharmacol. Ther. 1999, 65, 186.

   OpenUrl
7. 7.↵
   1. Freed M. I.,
   2. Allen A.,
   3. Jorkasky D. K.,
   4. DiCicco R. A.

   Systemic exposure to rosiglitazone is unaltered by food. Eur. J. Clin. Pharmacol. 1999, 55 (1), 53–56.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Cox P. J.,
   2. Ryan D. A.,
   3. Hollis F. J.,
   4. Harris A. M.,
   5. Miller A. K.,
   6. Vousden M.,
   7. Cowley H.

   Absorption, disposition and metabolism of rosiglitazone, a potent thaizolidinedione insulin sensitizer in humans. Drug Metab. Dispos. 2000, 28 (7), 772–780.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Radhakrishna T.,
   2. Satyanarayana J.,
   3. Satyanarayana A.

   LC determination of rosiglitazone in bulk and pharmaceutical formulation. J. Pharm. Biomed. Anal. 2002, 29 (5), 873–880.

   OpenUrlPubMed
10. 10.↵
    1. Gomes P.,
    2. Sippel J.,
    3. Jablonski A.,
    4. Steppe M.

    Determination of rosiglitazone in coated tablets by MEKC and HPLC methods. J. Pharm. Biomed. Anal. 2004, 36 (4), 909–913.

    OpenUrlPubMed
11. 11.↵
    1. Kolte B. L.,
    2. Raut B. B.,
    3. Deo A. A.,
    4. Bagool M. A.,
    5. Shinde D. B.

    Simultaneous determination of metformin in combination with rosiglitazone in pharmaceutical formulations. J. Chromatogr. Sci. 2004, 42 (2), 70–73.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Kolte B. L.,
    2. Raut B. B.,
    3. Deo A. A.,
    4. Bagool M. A.,
    5. Shinde D. B.

    Liquid chromatographic method for the determination of rosiglitazone in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 788 (1), 37–44.

    OpenUrlPubMed
13. 13.↵
    1. Gaffney M. H.,
    2. Allen G. D.,
    3. Abbott R. W.

    Determination rosiglitazone in plasma by HPLC with fluorescence detector. Methodol. Surv. Bioanal. Drugs. 1994, 23, 251.

    OpenUrl
14. 14.↵
    1. Muxlow A. M.,
    2. Fowles S.,
    3. Russell P.

    Automated high performance liquid chromatographic method for the determination of rosiglitazone in plasma. J. Chromatogr. B Biomed. Sci. Appl. 2001, 752 (1), 77–84.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Mamidi R. N.,
    2. Benjamin B.,
    3. Ramesh M.,
    4. Srinivas N. R.

    Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. Biomed. Chromatogr. 2003, 17 (6), 417–420.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Kim K. A.,
    2. Park J. Y.

    Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. Biomed. Chromatogr. 2004, 18 (8), 613–615.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Hruska M. W.,
    2. Frye R. F.

    Simplified method for the determination of rosiglitazone in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2004, 803 (2), 317–320.

    OpenUrlPubMed
18. 18.↵
    1. Lin Z. J.,
    2. Desai-Krieger D.,
    3. Shum L.

    Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography–tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2004, 801 (2), 265–272.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Ho E. N.,
    2. Yiu C. H.,
    3. Wan S. M.,
    4. Stewart B. D.,
    5. Watkins K. L.

    Detection of anti-diabetics in equine plasma and urine by liquid chromatography–tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 811 (1), 65–73.

    OpenUrlPubMedWeb of Science
20. 20.↵
    1. Soglia J. R.,
    2. Harriman S. P.,
    3. Zhao S.

    The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography–micro-electrospray ionization–tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J. Pharm. Biomed. Anal. 2004, 36 (1), 105–116.

    OpenUrlCrossRefPubMed
21. 21.↵
    International Conference on Harmonization, Topic Q2B, Validation of Analytical Methods: Methodology. Third International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Yokohama, Japan, 1997.
22. 22.↵
    U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. http://www.fda.gov/cder/guidance/index.htm (2001).
23. 23.↵
    U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Guidance for Industry. Animal Models—Essential Elements to Address Efficacy Under the Animal Rule, 2009.
24. 24.↵
    Committee for the Purpose of Control and Supervision of Experiments on Animals—CPCSEA. Guidelines for the laboratory animal facility. Indian J. Pharmacol. 2003, 35 (4), 257–274.

    OpenUrl